Sundström-Poromaa, I., Comasco, E., Sumner, R., & Luders, E. (2020). Progesterone - Friend or foe? Frontiers in Neuroendocrinology, 59, 100856. https://doi.org/10.1016/j.yfrne.2020.100856
Sundström-Poromaa I, Comasco E, Sumner R, Luders E. Progesterone - Friend or foe? Front Neuroendocrinol. 2020;59:100856. doi:10.1016/j.yfrne.2020.100856
Sundström-Poromaa, Inger, et al. "Progesterone - Friend or foe?" Frontiers in Neuroendocrinology, vol. 59, 2020, pp. 100856.
For EndNote, Zotero or Mendeley:
Open access
No open license is recorded for this paper. Reuse terms are set by the publisher.
Progesterone can help and harm mood in different women
A 2020 narrative review of human and animal research finds that a progesterone byproduct helps treat postpartum depression but may worsen premenstrual dysphoric disorder. The byproduct is allopregnanolone. The authors say knowledge of its benefits and harms is still limited.
Key Findings
In women of childbearing age, 18% have at least one mood symptom in the luteal phase, and 2–5% meet criteria for PMDD.
Women with PMDD show progesterone and allopregnanolone levels similar to healthy women. Their worst symptoms arrive late in the luteal phase, as levels fall.
Three placebo-controlled randomized trials of hormonal contraception in healthy women exist. All three found small but significant shifts toward worse mood.
Large register studies put the risk of needing antidepressant treatment for contraceptive mood side effects at 0.9 out of 100 users. Surveys suggest around 4–10% have mood symptoms.
Brexanolone, in the authors' words allopregnanolone, was tested in three randomized controlled trials for postpartum depression. It acted rapidly, with results sustained over 30 days.
Interpretation
The paper is a narrative review by four researchers. The authors explain the opposite mood effects through individual sensitivity to hormone change, since women with PMDD have similar hormone levels to healthy women. They call for risk markers for progesterone sensitivity, and for studies that compare women with PMDD and women with postpartum depression.
RRM Context
Mood symptoms that follow the menstrual cycle point to the hormonal events of the cycle itself, and postpartum mood symptoms follow the hormonal shift after delivery. The review says the mechanism linking allopregnanolone to PMDD has not been established. It also says mood effects are a major reason women stop hormonal contraception. Restorative reproductive medicine treats the cycle as diagnostic information and looks for the cause of cyclic mood problems.
Our editorial summary of this paper, not the article's abstract.
Abstract
Estradiol is the "prototypic" sex hormone of women. Yet, women have another sex hormone, which is often disregarded: Progesterone. The goal of this article is to provide a comprehensive review on progesterone, and its metabolite allopregnanolone, emphasizing three key areas: biological properties, main functions, and effects on mood in women. Recent years of intensive research on progesterone and allopregnanolone have paved the way for new treatment of postpartum depression. However, treatment for premenstrual syndrome and premenstrual dysphoric disorder as well as contraception that women can use without risking mental health problems are still needed. As far as progesterone is concerned, we might be dealing with a two-edged sword: while its metabolite allopregnanolone has been proven useful for treatment of PPD, it may trigger negative symptoms in women with PMS and PMDD. Overall, our current knowledge on the beneficial and harmful effects of progesterone is limited and further research is imperative.